News & Updates
Filter by Specialty:
Delgocitinib ointment safely reduces symptoms in paediatric atopic dermatitis
Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.
Delgocitinib ointment safely reduces symptoms in paediatric atopic dermatitis
05 Oct 2021
COVID-19 in childhood cancer patients: What are the risk factors?
A large international database study has shown that children and adolescents with cancer have an elevated risk of severe or critical disease if infected with COVID-19. Furthermore, about half the patients receiving cancer therapy experienced modifications to their treatment regimens.
COVID-19 in childhood cancer patients: What are the risk factors?
04 Oct 2021
Acute abdomen, appendicitis may occur in children with COVID-19, MIS-C
Paediatric patients with COVID-19 or multisystem inflammatory syndrome in children (MIS-C) may develop acute abdomen, with or without appendicitis, a study in Latin America has found.
Acute abdomen, appendicitis may occur in children with COVID-19, MIS-C
04 Oct 2021
Childhood URTI, antibiotic exposure up susceptibility to atopic, allergic diseases in young adulthood
Individuals who had been exposed to upper respiratory tract infection (URTI) and antibiotics as a child are at heightened risks of atopic dermatitis and allergic skin diseases in their young adulthood, as reported in a study.
